GLP-1 Agonists and Other Approaches to Address Comorbidities in Psoriasis
It’s time for dermatology clinicians to rethink their understanding of obesity and their approach in addressing weight with psoriasis patients. That’s according to Dr. Jennifer Soung, associate professor at Harbor-UCLA Medical Center. Next Steps in Derm, in partnership with Skin of Color Update, interviewed Dr. Soung, who shares a comprehensive perspective in addressing psoriatic arthritis an …
It’s time for dermatology clinicians to rethink their understanding of obesity and their approach in addressing weight with psoriasis patients. That’s according to Dr. Jennifer Soung, associate professor at Harbor-UCLA Medical Center. Next Steps in Derm, in partnership with Skin of Color Update, interviewed Dr. Soung, who shares a comprehensive perspective in addressing psoriatic arthritis an … Continue reading "GLP-1 Agonists and Other Approaches to Address Comorbidities in Psoriasis"
A 45-year-old patient with no prior skin problems presents with this new rash and review of system is positive for finger joint pain and swollen fingers. The pain is worse in the morning and improves as the day goes on. A thorough review of the patient’s medical history and labs were negative for HIV, hepatitis B and C, renal and he … 
Bimekizumab (Bimzelx®) is a new injectable medication FDA approved for plaque psoriasis. It is the first and only FDA approved IL-17A and IL-17F inhibitor for this disease, but is also being used as an off-label option for other conditions including psoriatic arthritis and hidradenitis suppurativa. This Therapeutic Cheat Sheet will focus on the on and off label uses of bimekizumab.
Bimekizuma … 
Roflumilast is a non-steroidal topical cream that was FDA approved for the treatment of plaque psoriasis in 2022.1 Roflumilast selectively inhibits phosphodiesterase-4 (PDE-4), which is an enzyme that mediates inflammatory responses and has been shown to play a role in several dermatologic diseases.2 Prior to topical roflumilast, oral PDE-4 inhibitors have been investigated across a wide variety o … 
Apremilast (OTEZLA®) is a twice daily oral medication that is FDA approved for adults with plaque psoriasis, psoriatic arthritis and oral ulcers associated with Behçet’s Disease.1 This drug is being extended as an off-label treatment to target inflammation in a number of different conditions. This Therapeutic Cheat Sheet will focus on apremilast and its applications for different dermatologica …